Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
People diagnosed with cancer over a year ago and those who were not on treatment did not have a higher risk of hospitalization or death.
Researchers explore the relationship between gut bacteria and the body’s response to CAR-T therapy.
A vaccine designed to enhance T-cell activity could help CAR-T therapy work better against solid tumors.
The personalized CAR-T therapy prolonged cancer remission compared with standard therapy.
98% of people who received the customized immunotherapy responded to the one-time treatment.
The first two people treated with the “living drug” remained cancer-free for a decade and can be considered cured.
A look back at some of the most important science and treatment news Cancer Health covered this year.
Patients treated with Breyanzi CAR-T therapy remained in remission longer than those who received standard care.
Researchers are examining opportunities for immune-modulating approaches to improve outcomes and reduce side effects.
Half of patients treated with the customized T cells achieved complete remission.
Colorado University Cancer Center member Diana Cittelly, PhD, is studying the role of interleukin 13 receptor alpha 2 in brain metastases.
For Childhood Cancer Awareness Month, the National Cancer Institute’s Director Dr. Ned Sharpless reflects on childhood cancer progress.
A family physician diagnosed with chronic lymphocytic leukemia, Brian Koffman cofounded the CLL Society. He lives in Claremont, California.
Some people with blood cancers, however, may not be as well protected.
After a median follow-up of 13 months, four of the five patients had ongoing complete remission.
More than 70% of people treated with Abecma, a customized immunotherapy, experienced complete or partial remission.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.